Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...